Xconomy | Boston - Business + Technology in the Exponential Economy

Related Posts

Genzyme, Biogen Idec Stocks Mixed on Icahn News

Robert Buderi 11/15/07

Shares of Massachusetts’ two leading biotechs, Genzyme and Biogen Idec, showed a mixed response to last night’s news from SEC filings that activist investor Carl Icahn was showing increased interest in the firms. Biogen, where Icahn almost tripled his previous stake, to 8.8 millon shares, fell $0.09, to $69.92. Genzyme, where Icahn took a new stake of nearly 1 percent, rose $2.08 (nearly 3 percent), to $72.84.

Bob is Xconomy's founder and editor in chief. You can e-mail him at bbuderi@xconomy.com, call him at 617.500.5926, or follow him on Twitter at http://twitter.com/bbuderi.

Comments | Reprints | Share:   Retweet Facebook Email

Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    
Xconomy network map Seattle Boston San Diego
national life-sciences startups

Most Popular Stories

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009, Xconomy, Inc. XCONOMY is a registered service mark of Xconomy, Inc. All rights reserved.
Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.